These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8567825)

  • 21. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypothalamus-pituitary-ovarian axis in cyclic rats lacking progesterone actions.
    Sánchez-Criado JE; Galiot F; Bellido C; Gonzalez D; Tébar M
    Biol Reprod; 1993 Apr; 48(4):916-25. PubMed ID: 8485257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of LHRH analogues in gynaecology: a review.
    McLachlan RI; Healy DL; Burger HG
    Br J Obstet Gynaecol; 1986 May; 93(5):431-54. PubMed ID: 3085705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteinizing hormone releasing hormone analogues for contraception.
    Nillius SJ
    Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol.
    Smitz J; Erard P; Camus M; Devroey P; Tournaye H; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1992 Oct; 7(9):1225-9. PubMed ID: 1479002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
    Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Nugent D; Vandekerckhove P; Hughes E; Arnot M; Lilford R
    Cochrane Database Syst Rev; 2000; (4):CD000410. PubMed ID: 11034687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries.
    Homburg R; Eshel A; Kilborn J; Adams J; Jacobs HS
    Hum Reprod; 1990 Jan; 5(1):32-5. PubMed ID: 2108981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian steroid modulation of gonadotropin secretion and pituitary responsiveness to luteinizing hormone-releasing hormone in the female hamster.
    Shander D; Goldman B
    Endocrinology; 1978 Oct; 103(4):1383-93. PubMed ID: 369849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary pharmacological manipulation in assisted reproduction.
    Huirne JA; Lambalk CB; van Loenen AC; Schats R; Hompes PG; Fauser BC; Macklon NS
    Drugs; 2004; 64(3):297-322. PubMed ID: 14871171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
    Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
    Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation].
    Felberbaum R; Reissmann T; Zoll C; Küpker W; al-Hasani S; Diedrich C; Diedrich K
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():113-7. PubMed ID: 8672908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.